Loading clinical trials...

UNKNOWNNA

The Transitions Project: Efficacy Trial

Randomized Trial of an Intervention to Enhance Quality of Life in Adults Completing Lung Cancer Treatment With Curative Intent

NCT05087251•Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate the efficacy of a brief psychoeducational intervention to improve quality of life in patients with lung cancer who are transitioning from active treatment to surveillance.

Detailed Description

This is a randomized controlled trial to test the efficacy of a brief psychoeducational intervention relative to a control condition for improving quality of life in patients with lung cancer who are transitioning from treatment to surveillance. In this study, participants will complete survey questions and will be randomly assigned to receive a 5-session program or a 1-session program. It is expected that about 100 people will take part in this research study. The American Lung Association is supporting this research by providing funding for the research study.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 21 or older
•Able to read and respond in English
•Diagnosis of non-small cell lung cancer or small cell lung cancer
•Documented curative treatment plan including systemic therapy +/- radiation and +/- surgery
•Completed cancer treatment within past 3 weeks
•* If final treatment is systemic therapy +/- radiation: within 3 weeks after cancer care team determination that treatment is complete
•* If final treatment is surgery: within 3 weeks after hospital discharge following surgery

Exclusion Criteria

•Comorbid health condition that would interfere with study participation
•Current participation in cognitive behavioral therapy treatment

Locations (2)

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Key Dates

Start Date

September 30, 2021

Primary Completion Date

March 30, 2023

Completion Date

June 30, 2023

Last Updated

November 14, 2022

Enrollment

100

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Five Psycho-educational Session(s)

BEHAVIORAL

One Psycho-educational Session(s)

BEHAVIORAL

Contacts

Lara Traeger, PhD

CONTACT

(617) 643-4314 LTRAEGER@mgh.harvard.edu

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

RECRUITINGPHASE2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

NCT05692635

Brain MetastasesNonsmall Cell Lung Cancer Stage III

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Transitions Project: Efficacy Trial

Inclusion Criteria

Exclusion Criteria

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Magnetic Resonance Imaging of the Lung: Oncological Applications

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors